Tempest Therapeutics, Inc. (TPST)Healthcare | Biotechnology | Brisbane, United States | NasdaqCM
1.96 USD
-0.28
(-12.500%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.98 +0.02 (1.020%) ⇧ (April 17, 2026, 7:43 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 18, 2026, 11:36 p.m. EDT
Despite recent price recovery toward resistance, TPST remains a high-risk speculative vehicle with negative adjusted 45-day forecast (-16%), deteriorating fundamentals, and no dividend payout. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.315558 |
| AutoETS | 0.324786 |
| AutoARIMA | 0.324787 |
| MSTL | 0.336458 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 27.10 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.283 |
| Excess Kurtosis | 0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 122.091 |
| Market Cap | 28,114,310 |
| Forward P/E | -1.62 |
| Beta | -1.89 |
| Previous Name | Tempest Therapeutics Inc. |
| Website | https://www.tempesttx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7243319 |
| Address1 | 2,000 Sierra Point Parkway |
| Address2 | Suite 400 |
| All Time High | 162,893.25 |
| All Time Low | 1.5 |
| Ask | 1.99 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 426,980 |
| Average Daily Volume3 Month | 200,248 |
| Average Volume | 200,248 |
| Average Volume10Days | 426,980 |
| Beta | -1.89 |
| Bid | 1.92 |
| Bid Size | 1 |
| Book Value | 1.353 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.96 |
| Current Ratio | 2.495 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 2.2745 |
| Day Low | 1.8 |
| Debt To Equity | 122.091 |
| Display Name | Tempest Therapeutics |
| Dividend Date | 1,544,400,000 |
| Earnings Timestamp | 1,774,873,800 |
| Earnings Timestamp End | 1,778,675,400 |
| Earnings Timestamp Start | 1,778,675,400 |
| Ebitda | -26,309,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.085 |
| Enterprise Value | 28,548,306 |
| Eps Current Year | -1.34 |
| Eps Forward | -1.21 |
| Eps Trailing Twelve Months | -6.33 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.122 |
| Fifty Day Average Change | -0.16199994 |
| Fifty Day Average Change Percent | -0.076343045 |
| Fifty Two Week Change Percent | -72.43319 |
| Fifty Two Week High | 12.23 |
| Fifty Two Week High Change | -10.2699995 |
| Fifty Two Week High Change Percent | -0.83973837 |
| Fifty Two Week Low | 1.5 |
| Fifty Two Week Low Change | 0.46000004 |
| Fifty Two Week Low Change Percent | 0.3066667 |
| Fifty Two Week Range | 1.5 - 12.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,730,600,000 |
| Float Shares | 9,270,549 |
| Forward Eps | -1.21 |
| Forward P E | -1.6198347 |
| Free Cashflow | -17,585,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.35369998 |
| Held Percent Institutions | 0.29413 |
| Implied Shares Outstanding | 14,344,035 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,744,156,800 |
| Last Split Factor | 1:13 |
| Long Business Summary | Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. |
| Long Name | Tempest Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 28,114,310 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_552715229 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -26,262,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 28,114,306 |
| Number Of Analyst Opinions | 1 |
| Open | 2.24 |
| Operating Cashflow | -26,820,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 415 798 8589 |
| Post Market Change | 0.01999998 |
| Post Market Change Percent | 1.0204072 |
| Post Market Price | 1.98 |
| Post Market Time | 1,776,469,430 |
| Prev Name | Tempest Therapeutics Inc. |
| Previous Close | 2.24 |
| Price Eps Current Year | -1.4626865 |
| Price Hint | 4 |
| Price To Book | 1.4486326 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.326 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.28 |
| Regular Market Change Percent | -12.5 |
| Regular Market Day High | 2.2745 |
| Regular Market Day Low | 1.8 |
| Regular Market Day Range | 1.8 - 2.2745 |
| Regular Market Open | 2.24 |
| Regular Market Previous Close | 2.24 |
| Regular Market Price | 1.96 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 496,118 |
| Return On Assets | -0.56863 |
| Return On Equity | -2.03629 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 14,344,034 |
| Shares Percent Shares Out | 0.0313 |
| Shares Short | 449,002 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 170,218 |
| Short Name | Tempest Therapeutics, Inc. |
| Short Percent Of Float | 0.077800006 |
| Short Ratio | 2.41 |
| Source Interval | 15 |
| State | CA |
| Symbol | TPST |
| Target High Price | 11.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 11.0 |
| Target Median Price | 11.0 |
| Total Cash | 7,707,000 |
| Total Cash Per Share | 0.537 |
| Total Debt | 8,141,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -6.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.854625 |
| Two Hundred Day Average Change | -3.8946252 |
| Two Hundred Day Average Change Percent | -0.6652219 |
| Type Disp | Equity |
| Volume | 496,118 |
| Website | https://www.tempesttx.com |
| Zip | 94,005 |